Navigation Links
Study Shows Pine Bark Naturally Reduces Blood Pressure and Counteracts Kidney Damage Caused by Hypertension

HOBOKEN, N.J., March 3 /PRNewswire/ -- An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases.  A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults.  Chronically high blood pressure damages capillaries of the kidneys which in turn affects the organ's ability to filter waste and remove excess fluids from the body.  A study published in the March 2010 issue of the Journal of Cardiovascular Pharmacology and Therapeutics reveals Pycnogenol® (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, counteracts kidney damage caused by hypertension, lowering urinary proteins and improving blood flow to the kidneys.

"Kidney disease is a common problem for people with hypertension and is an equally 'silent' threat to the body.  There are no warning signals and inefficient fluid removal may further increase the blood pressure, causing a vicious circle to set in," said Dr. Gianni Belcaro, a lead researcher of the study.  "The results of this study demonstrated Pycnogenol®'s ability not only to reduce blood pressure, but also to relieve the kidney damage caused by chronic hypertension."

The randomized, controlled study conducted by the G D'Annunzio University in Italy investigated 55 hypertensive patients who showed early signs of impaired kidney function, as judged by elevated amounts of proteins found in their urine.  The patients were divided into two groups.  Both groups were treated with anti-hypertensive medication Ramipril and one group of 29 patients took Pycnogenol in addition to the Ramipril.  Urine was collected during a 24 hour period for quantification of protein (albumin) at baseline and again after six months of treatment.

All patients included in the study had an average urinary protein level of 89 mg per 24-hour period, significantly exceeding the 30 mg measure, up to which kidney function is considered sufficient.  After six months of treatment with Ramipril, average protein levels decreased to 64 mg per 24-hour period, remaining well above an acceptable level.  Conversely, the group taking Pycnogenol® as an adjunct to Ramipril had an average of only 39 mg per 24-hour period, a decrease of nearly double compared with anti-hypertensive medication taken alone.

The study also found a statistically significant decrease in patients' blood pressure when taking Pycnogenol® in conjunction with Ramipril.  When treated exclusively with Ramipril, systolic blood pressure values dropped by more than 30 percent and diastolic blood pressure values dropped approximately eight percent.  The addition of Pycnogenol® decreased both systolic and diastolic pressures by an additional three to six percent.  Pycnogenol® was also found to lower the patients' elevated levels of inflammatory marker CRP, a blood protein associated with the risk for acute cardiovascular events such as heart attack, reducing values to a healthy level.

"While Ramipril represents an effective treatment for hypertension and its interrelated effects on kidney function, Pycnogenol® as an adjunct to the medication produced significantly greater results, particularly for kidney function restoration," said Dr. Belcaro.  "Pycnogenol® continues to demonstrate its abilities as a natural solution for the complete cardiovascular system."

Previous studies have revealed Pycnogenol® to favorably affect the normalization of blood pressure by releasing arterial constriction.

About Pycnogenol®

Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits.  The extract has been widely studied for the past 40 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient.  Today, Pycnogenol® is available in more than 700 dietary supplements, multi-vitamins and health products worldwide.  For more information, visit

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research.  Pycnogenol® is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents.  Horphag Research Ltd. Is the recipient of the 2008 Frost & Sullivan North American Health Ingredients Excellence in Research Award.  NHS has the exclusive rights to market and sell Pycnogenol® in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement.  For more information about Pycnogenol visit our Web site at

SOURCE Natural Health Science Inc.

Back to top



SOURCE Natural Health Science Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
2. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
3. SCAI Statement on the CREST Study Findings: Carotid Stenting is as Safe and Effective as Carotid Surgery in Patients at Risk for Stroke
4. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
5. Americas Biopharmaceutical Companies Studying 183 New Medicines to Counter Diabetes Growth
6. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
7. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
8. Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity
9. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
10. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
11. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Post Your Comments:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):